Back to the articles list | Back to browse issues page

XML Print

The effect of Sinopharm COVID-19 vaccine on fecal calprotectin levels and clinical symptoms in patients with ulcerative colitis
Babak Tamizifar1 , Nazila Kassaian2 , Marzieh Rahimkhorasani3 , Hazhir Moradi2 , Somaieh Sabzali4 , Kiana Shahzamani5 , Peyman Adibi1
1- Isfahan Gastroenterology and Hepatology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
2- Nosocomial Infection Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
3- Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
4- Department of Biology, Faculty of Basic Sciences, Lorestan University, Khorramabad, Iran
5- Hepatitis Research Center, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran , shahzamani.k@lums.ac.ir
Abstract:   (1511 Views)
Background: The ongoing COVID-19 pandemic has raised concerns regarding the safety and efficacy of vaccination in immunocompromised patients, including those with inflammatory bowel disease (IBD). In this study, we aimed to investigate the effect of the Sinopharm anti-COVID-19 vaccine on fecal calprotectin (fCP) levels and clinical symptoms in patients with ulcerative colitis (UC).
Methods: A total of 28 patients with UC (8 females and 20 males), with a mean age of 40.8 ± 9.7 years, were enrolled in the study. Most patients were receiving 5-aminosalicylic acid (5-ASA) agents. All patients received the Sinopharm anti-COVID-19 vaccine. Fecal calprotectin levels and clinical symptoms were assessed at baseline and at 2 and 12 weeks after vaccination. The Lichtiger score and Mayo score were used to evaluate clinical symptoms.
Results: No IBD-related adverse events were reported following vaccination. There was no significant difference in fCP levels between baseline and 2 weeks after vaccination. However, a significant decrease in fCP levels was observed at 12 weeks after vaccination compared to baseline and 2 weeks post-vaccination. Similarly, a significant improvement in clinical symptoms was noted at 2 and 12 weeks after vaccination compared to baseline, as evidenced by a reduction in the Lichtiger score. There was no association between vaccination and the clinical bleeding score (Mayo score). None of the other parameters, including location of injury, type of medication, or sex, were associated with fCP levels, Lichtiger score, or Mayo score.
Conclusion: The results of this study suggest that the Sinopharm anti-COVID-19 vaccine is safe for patients with IBD and does not lead to exacerbation of UC symptoms.
Keywords: Inflammatory Bowel Disease, Colitis, Ulcerative, COVID-19, Vaccines, Safety, Fecal calprotectin
Full-Text [PDF 328 kb]   (430 Downloads) |   |   Full-Text (HTML)  (125 Views)  
Research Article: Research Article | Subject: Virology
Received: 2025/02/24 | Accepted: 2025/08/27
References
1. Morens DM, Daszak P, Taubenberger JK. Escaping Pandora's box-another novel coronavirus. N Engl J Med. 2020;382(14):1293-5. [View at Publisher] [DOI] [PMID] [Google Scholar]
2. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020;323(18):1775-6. [View at Publisher] [DOI] [PMID] [Google Scholar]
3. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-42. [View at Publisher] [DOI] [PMID] [Google Scholar]
4. Rezaei M, Sabzali S, Satari M, Parhamfar M. Immunoinformatics Vaccine targeting S1-NTD and HA2 to against SARS-CoV-2 and Influenza. Research in Molecular Medicine. 2023;11(3):10-26. [View at Publisher] [Google Scholar]
5. Team CC-R. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019-United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(13):382-6. [View at Publisher] [DOI] [PMID] [Google Scholar]
6. Gao F, Zheng KI, Wang X-B, Sun Q-F, Pan K-H, Wang T-Y, et al. Obesity is a risk factor for greater COVID-19 severity. Diabetes care. 2020;43(7):e72-e4. [View at Publisher] [DOI] [PMID] [Google Scholar]
7. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829-38. [View at Publisher] [DOI] [PMID] [Google Scholar]
8. Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology. 2018;155(2):337-46.e10. [View at Publisher] [DOI] [PMID] [Google Scholar]
9. Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8(6):443-68. [View at Publisher] [DOI] [PMID] [Google Scholar]
10. Tinsley A, Navabi S, Williams ED, Liu G, Kong L, Coates MD, et al. Increased risk of influenza and influenza-related complications among 140,480 patients with inflammatory bowel disease. Inflamm Bowel Dis. 2019;25(2):369-76. [View at Publisher] [DOI] [PMID] [Google Scholar]
11. Feldmann M, Maini RN, Woody JN, Holgate ST, Winter G, Rowland M, et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020;395(10234):1407-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
12. Michot J-M, Albiges L, Chaput N, Saada V, Pommeret F, Griscelli F, et al. Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. Ann Oncol. 2020;31(7):961-4. [View at Publisher] [DOI] [PMID] [Google Scholar]
13. Wong S-Y, Dixon R, Pazos VM, Gnjatic S, Colombel J-F, Cadwell K, et al. Serologic response to messenger RNA coronavirus disease 2019 vaccines in inflammatory bowel disease patients receiving biologic therapies. Gastroenterology. 2021;161(2):715-8. e4. [View at Publisher] [DOI] [PMID] [Google Scholar]
14. Watad A, De Marco G, Mahajna H, Druyan A, Eltity M, Hijazi N, et al. Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 vaccination. Vaccines. 2021;9(5):435. [View at Publisher] [DOI] [PMID] [Google Scholar]
15. Siegel CA, Melmed GY, McGovern DP, Rai V, Krammer F, Rubin DT, et al. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut. 2021;70(4):635-40. [View at Publisher] [DOI] [PMID] [Google Scholar]
16. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-15. [View at Publisher] [DOI] [PMID] [Google Scholar]
17. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-16. [View at Publisher] [DOI] [PMID] [Google Scholar]
18. Botwin GJ, Li D, Figueiredo J, Cheng S, Braun J, McGovern DP, et al. Adverse events following SARS-CoV-2 mRNA vaccination among patients with inflammatory bowel disease. Am J Gastroenterol. 2021;116(8):1746-51. [View at Publisher] [DOI] [PMID] [Google Scholar]
19. Pokryszka J, Wagner A, Wiedermann U, Tobudic S, Herkner H, Winkler S, et al. Course of Fecal Calprotectin after mRNA SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Diseases. Vaccines (Basel). 2022;10(5):759. [View at Publisher] [DOI] [PMID] [Google Scholar]
20. Walsham NE, Sherwood RA. Fecal calprotectin in inflammatory bowel disease. Clin Exp Gastroenterol. 2016:9:21-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
21. Higgins PD, Harding G, Revicki DA, Globe G, Patrick DL, Fitzgerald K, et al. Development and validation of the Ulcerative Colitis patient-reported outcomes signs and symptoms (UC-pro/SS) diary. J Patient Rep Outcomes. 2017;2(1):26. [View at Publisher] [DOI] [PMID] [Google Scholar]
22. Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JHJIbd. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14(12):1660-6. [View at Publisher] [DOI] [PMID] [Google Scholar]
23. World Health Organization (WHO). COVID-19 Vaccine (Vero Cell), Inactivated, CoronaVac. 2021;23:2021. [View at Publisher]
24. Tabesh E, Soheilipour M, Rezaeisadrabadi M, Zare-Farashbandi E, Mousavi-Roknabadi RSJBg. Comparison the effects and side effects of Covid-19 vaccination in patients with inflammatory bowel disease (IBD): a systematic scoping review. BMC Gastroenterol. 2022;22(1):393. [View at Publisher] [DOI] [PMID] [Google Scholar]
25. Fiorino G, Peyrin-Biroulet L, Naccarato P, Szabò H, Sociale OR, Vetrano S, et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2012;18(6):1042-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
26. Bar-Zeev N, Inglesby T. COVID-19 vaccines: early success and remaining challenges. Lancet. 2020;396(10255):868-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
27. Farkas K, Matuz M, Kata D, Földesi I, Resál T, Bacsur P, et al. P444 COVID-19 risk factors, infection course and vaccination among patients with inflammatory bowel disease based on a Hungarian cohort. J Crohns Colitis. 2022;16(Supplement_1):i425-i. [View at Publisher] [DOI] [Google Scholar]
28. World Health Organization (WHO). The Sinopharm COVID-19 vaccine: What you need to know. WHO News Room – Feature Stories. 2021. [View at Publisher]
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.